Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-004
- Development stage
- Preclinical
- Lead developer
- Sunny Pharmtech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SP-004 is a small molecule therapeutic candidate being developed by Sunny Pharmtech for the treatment of pulmonary fibrosis. Formulated as an oral softgel capsule, the drug is classified by the developer as a high-potency compound with an Occupational Exposure Band (OEB) level of 3. Sunny Pharmtech, a Contract Development and Manufacturing Organization (CDMO), currently lists the product in the R&D and pilot batch stages of development, which typically corresponds to the IND-enabling phase. While the specific molecular target and active pharmaceutical ingredient have not been publicly disclosed, the program focuses on providing a specialized oral formulation for fibrotic lung disease.
Beyond the preview
Go deeper on SP-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-004.